Clin2
NCT06199895Possibly a fitRecruiting

Study of paclitaxel for patients with taxane-resistant solid tumors

Pancreatic AdenocarcinomaCholangiocarcinomaLung CancerStomach CancerEsophageal CarcinomaBreast Cancer

Treatments studied

Part of Cancer, Digestive system, Lungs & breathing, Skin clinical trials.

This trial tests paclitaxel given as tiny micelle particles for people whose cancer (pancreatic, bile duct, lung, stomach, esophagus, or breast) stopped responding to taxane chemotherapy or did not shrink. The goal is to see if this treatment can help when standard taxanes no longer work.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
25 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You are 18 years or older
  • You have advanced cancer of the pancreas, bile ducts, lung, stomach, esophagus, or breast with a measurable tumor
  • Your cancer has become resistant to a taxane drug (like paclitaxel or docetaxel), meaning it didn’t shrink or came back after treatment
  • You are in generally good health (able to care for yourself, up and about more than half the day)
  • Your blood counts and liver/kidney function are within certain safe limits
  • You are not pregnant and agree to use effective birth control during the study and for 6 months after

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06765590Recruiting
Paclitaxel (albumin-bound) bioequivalence study in breast cancer

This study tests whether a new version of paclitaxel (albumin-bound) works the same as the approved version in people with breast cancer. It's for patients whose cancer has spread or returned after other treatments, or those for whom this drug is recommended by treatment guidelines.

Luoyang, Henan
NCT07795749Recruiting· Phase 2
Intraperitoneal paclitaxel with systemic therapy for gastrointestinal cancer with peritoneal spread

This study tests a treatment that combines chemotherapy given directly into the abdomen (intraperitoneal) with standard systemic chemotherapy for people whose gastrointestinal cancer has spread to the lining of the abdomen (peritoneal carcinomatosis). It aims to control the cancer and improve how patients feel.

Orange, California
NCT05183126Recruiting· Phase 4
Paclitaxel dose study using a 1-hour muscle-area infusion

This trial studies how paclitaxel (a chemotherapy medicine) behaves in the body when given by a specific 1-hour infusion approach. It may help refine dosing for people with cancer using measurements from scans, and it includes a medicine schedule you must match.

Ann Arbor, Michigan
NCT06752811Recruiting· Phase 3
Testing a new paclitaxel formula for advanced pancreatic cancer

This trial tests a new form of the chemotherapy drug paclitaxel (called polymeric micellar paclitaxel) for people with pancreatic cancer that has spread to other parts of the body (metastatic). It's for those who haven't had any prior treatment for their metastatic cancer, and aims to see if this drug can help control the cancer.

Nanjing, Jiangsu
NCT07662746Recruiting· Phase 2
Paclitaxel micelles for advanced head and neck cancer

This trial tests a new form of chemotherapy called paclitaxel polymeric micelles for people with head and neck cancer that has come back or spread. It is for patients who have already tried one line of treatment and may benefit from a different option.

Shanghai, Shanghai Municipality
NCT06632574Recruiting· Phase 1
Paclitaxel liposomes via artery for advanced solid tumors

This trial tests a new form of paclitaxel (a chemotherapy drug) wrapped in tiny fat bubbles called liposomes. It is given directly into an artery that feeds the tumor, which may deliver the drug more effectively to the cancer. The study is for people with advanced solid tumors that can be treated this way, such as stomach, liver, pancreatic, or lung cancers.

Nanjing

Hear when a new Pancreatic Adenocarcinoma trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.